Eisai and Biogen Win China Approval for LEQEMBI SC
Tokyo, Japan and Cambridge, Massachusetts, USA, September 3, 2026 Eisai Co., Ltd. and Biogen Inc. announced that China’s National...
Eisai
Advertisement
Eisai and Biogen Advance LEQEMBI Access in Canada
TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...
Eisai and Biogen Launch LEQEMBI IQLIK for Alzheimer’s
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
Eisai Grants CORE Exclusive Global Oncology Rights
BOSTON, Mass. and TOKYO, Japan, July 28, 2026 CORE Biomedicine has entered into an exclusive global licensing agreement with...
Eisai Advances Alzheimer’s Care with LEQEMBI IQLIK Approval
TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...
Advertisements
Eisai Showcases Alzheimer’s Research at AAIC 2026 Meeting
TOKYO, June 29, 2026 Eisai Co., Ltd. has announced it will present more than 50 scientific presentations highlighting the...
Eisai and Biogen Receive FDA Extension for LEQEMBI
TOKYO and CAMBRIDGE, Mass., May 8, 2026 Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and...
Eisai Nuvation Taletrectinib EMA MAA Validation
Tokyo & New York – March 27, 2026 Eisai and Nuvation Bio announced that the European Medicines Agency (EMA)...
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
FDA Accepts LEQEMBI sBLA, Expanding At-Home Alzheimer’s Therapy
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
Advertisement
